Case Conversation: Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin)

January 10, 2024

This is a recorded version of the journal club program, Case Conversation: Recombinant VWF and TXA for HMB in patients with mild and moderate VWD in the USA, that was presented live on January 10, 2024.  Please scroll all the way down this page to view the archived program.

Webinar Date: 1/10/2024
Estimated Time to complete: 1 hour
Format: Archived Case Conversation (Journal Club)
Target Audience: This activity is designed for women’s healthcare professionals, including obstetricians, gynecologists, pediatric/adolescent gynecologists, advanced practice providers, and nurses specializing in women’s health are the primary target audience to ensure optimal comprehensive care. The identified professionals will also benefit from understanding the importance of collaborating with hematology colleagues to better manage heavy menstrual bleeding across the lifespan.

Program Description:
Among females with von Willebrand disease, up to 80% have heavy menstrual bleeding. The scarcity of effective treatment for heavy menstrual bleeding remains a major unmet healthcare need. International guidelines indicate low certainty regarding the effectiveness of hormonal therapy and tranexamic acid. Although von Willebrand factor (VWF) concentrate is approved for bleeds, no prospective trials guide its use in heavy menstrual bleeding. This study aimed to compare recombinant VWF with tranexamic acid for reducing heavy menstrual bleeding in patients with von Willebrand disease.

This case conversation will address the following learning objectives:

  1. Identify the unmet needs of women with heavy menstrual bleeding (HMB).
  2. Describe the scope of associated morbidity of HMB.
  3. List the current approaches to HMB and the drawbacks of each.
  4. Review key points for a balanced discussion with patients.
  5. Consider potential future studies to address HMB.

Margaret Ragni, MD, MPH

University of Pittsburgh Medical Center
Medical Director
Hemophilia Center of Western Pennsylvania

Nicoletta Machin, DO, MS
University of Pittsburgh Medical Center
Hemophilia Center of Western Pennsylvania